Anika Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $287.1M | $94.4M |
| FY2022 | — | $285.6M | $86.3M |
| FY2023 | — | $212.3M | $68.7M |
| FY2024 | — | $154.0M | $55.6M |
| FY2025 | — | $143.5M | $57.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $287.1M | $94.4M |
| FY2022 | — | $285.6M | $86.3M |
| FY2023 | — | $212.3M | $68.7M |
| FY2024 | — | $154.0M | $55.6M |
| FY2025 | — | $143.5M | $57.5M |